Noradrenergic involvement in catalepsy induced by Δ9-tetrahydrocannabinol
References (15)
- et al.
Cholinergic and neuroleptic induced catalepsy; modification by lesions in the globus pallidus and substantia nigra
Neuropharmacology
(1971) - et al.
Facilitation of muricide by dorsal norepinephrine bundle lesions in olfactory bulbectomized rats
Pharmac. Biochem. Behav.
(1978) - et al.
Hyperdipsia induced by bilateral destruction of the locus coeruleus in rats
Brain Res.
(1975) Abnormal behavior induced by Δ9-tetrahydrocannabinol and its pharmacological characteristics
Trends pharmacological Sci
(1980)- et al.
Effects of midbrain raphe stimulation and lesion on EEG activity in rats
Brain Res. Bull.
(1979) - et al.
Norepinephrine-dopamine interactions and behavior
Science
(1977) - et al.
Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes
J. Pharmac. exp. Ther.
(1975)
Cited by (22)
Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects
2018, Life SciencesCitation Excerpt :As it has been previously described, cannabinoids elicit a general stimulation of LC cells in vivo with an increase in the activity of TH and NA efflux in the brain, which could contribute to cannabinoid-induced effects (see concluding remarks and future perspectives section). In behavioural studies, cannabinoids were shown to produce aversive behaviour, catalepsy, antinociception, hypothermia and antidepressant effects via NA neurotransmission or activation of LC nucleus [21,28,58,121]. Thus, destruction of NA neurons decreased the antinociceptive effect of methandamide, a synthetic analogue of anandamide, in the tail immersion or hot plate tests [63].
The amnesic effect of intra-central amygdala administration of a cannabinoid CB1 receptor agonist, WIN55,212-2, is mediated by a beta-1 noradrenergic system in rat
2012, NeuroscienceCitation Excerpt :In addition, participation of the endocannabinoid system of the amygdala in the regulation of memory processes has been proposed (for review see Casswell and Marks, 1973; Marco and Viveros, 2009). In many studies, interaction between adrenoceptors and cannabinoid receptor functions has been reported (Singh and Das, 1976; Kataoka et al., 1987; Lichtman and Martin, 1991; Moshfegh et al., 2011). According to research, acute administration of WIN55,212-2 increased NE efflux in the frontal cortex and stimulates c-Fos expression in noradrenergic neurons of the LC (Oropeza et al., 2005).
β1-noradrenergic system of the central amygdala is involved in state-dependent memory induced by a cannabinoid agonist, WIN55,212-2, in rat
2011, Behavioural Brain ResearchCitation Excerpt :Conversely, administration of β-adrenergic receptor antagonists impaired learning and memory in behavioural studies [30–36]. Documentation exists regarding interaction between noradrenergic and cannabinoid receptor functions [10,37–39]. According to research, genetic and pharmacological manipulation of the endocannabinoid system can influence the cerebral monoamine tone [40–42].
CB<inf>1</inf> cannabinoid receptors inhibit the glutamatergic component of KCl-evoked excitation of locus coeruleus neurons in rat brain slices
2007, NeuropharmacologyCitation Excerpt :Finally, given the relevance of glutamatergic systems in the LC during drug addiction (Nestler and Aghajanian, 1997) and the contribution of the LC in the regulation of several behavioral, cognitive and reinforcing functions influenced by cannabinoids (Kataoka et al., 1987; Jentsch et al., 1997; Nestler and Aghajanian, 1997), our study may be of interest to better understand the pharmacological properties of marijuana.
Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats
2006, European Journal of Pharmacology
- ∗
Present addresses: 2nd Department of Pharmacology, School of Medicine, Nagasaki University, Nagasaki 852, Japan.
- †
Present addresses: Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-01, Japan.
- ‡
Department of Pharmacology, Okayama University Medical School, Okayama 700, Japan.